Form 4: Dynavax COO Novack Sells 114,000 Shares

Dynavax Technologies Corp. President & COO David F. Novack exercised options and sold 114,000 shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• David F. Novack, President & COO of Dynavax Technologies Corp., engaged in transactions on January 15, 2026.
• Novack acquired 20,000 shares of common stock by exercising stock options at a price of $6.805 per share.
• Novack acquired an additional 94,000 shares of common stock by exercising stock options at a price of $10.47 per share.
• Concurrently, Novack sold 114,000 shares of common stock at a weighted average price of $15.64 per share, with individual trades ranging from $15.585 to $15.665.
• These sales were executed under a Rule 10b5-1 trading plan adopted on December 6, 2024.
• Following these transactions, Novack directly beneficially owns 63,344 shares of common stock.
• Novack also holds 146,528 stock options with an exercise price of $6.805, exercisable until December 15, 2026.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions (option exercise and sale) under a pre-arranged 10b5-1 plan. While insider selling can sometimes be viewed negatively, the pre-planned nature mitigates immediate concerns about new negative information. The transactions are neutral in terms of company performance, reflecting executive compensation management.

Positives

• The exercise of options indicates the options were in-the-money, suggesting a market price higher than the exercise price at the time of transaction.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces direct insider ownership.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may observe a reduction in direct insider ownership, which could be interpreted in various ways, though the 10b5-1 plan suggests a pre-planned financial management strategy by the executive.

Key Dates

Recommendation

The Form 4 filing details routine insider transactions (option exercise and subsequent sale) by a key executive under a pre-established 10b5-1 trading plan. Such pre-planned sales are typically for personal financial management and do not usually signal a change in the company's fundamental outlook or performance. Therefore, this filing alone does not provide sufficient new information to warrant a change in investment recommendation; a 'hold' stance is maintained pending further operational or financial updates.

Keywords

Dynavax Technologies, DVAX, David F. Novack, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, Share Sale, Executive Compensation